Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus irinotecan in recurrent or progressive malignant glioma
2009-015036-15Phase 2Completed
- Sponsor
- Medical University of Innsbruck
- Start
- Nov 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and irinotecan in malignant glioma, glioma and glioblastoma (GBM), sponsored by Medical University of Innsbruck. Primary endpoint: Objective response criteria by MRI and FET-/FLT-PET. Started Nov 2009; status: completed.
02
Drugs
bevacizumabirinotecan
03
Conditions
malignant gliomagliomaglioblastoma (GBM)
Beyond the preview
Go deeper on 2009-015036-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015036-15.